Antimicrobial resistance, especially Gram-negative bacteria, is an increasing health threat, according to the World Health OrganizationExternal link. Gram-negative bacteria can cause a range of infections including certain types of pneumonia and sexually transmitted diseases such as gonorrhoea. One species of the bacteria, E.coli, is a common cause of foodborne disease.
Fluoroquinolones, the previous class of antibiotics to reach the market against these microorganisms, were developed in the 1960s and are losing their effectiveness. This had made the search for new antibiotics an urgent priority but, to date, no clinical antibiotics have targeted the outer membrane of the bacteria, essential to protect cells from antibiotics.
In a study published on Wednesday in science journal NatureExternal link, researchers at the University of ZurichExternal link in collaboration with pharmaceutical company Polyphor have discovered antibiotics that interact with essential outer membrane proteins in Gram-negative bacteria.
The antibiotics destroy the integrity of the outer membrane of the Gram-negative bacteria, which has the important function of protecting the bacteria from toxic environmental factors, such as antibiotics. This causes the bacteria to die slowly. In contrast to existing antibiotics, this new class has not shown any resistance.
Polyphor, a former University of Zurich start-up founded in 1996, is developing one of the compounds for clinical trials.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Geneva researchers discover molecule responsible for tissue damage in heart attacks
This content was published on
A research team in Switzerland has discovered the lipid responsible for killing tissue during a heart attack, offering new hope for treatments.
University of Zurich and Arnold Schwarzenegger seal climate deal
This content was published on
The University of Zurich has signed a sustainable finance deal with Hollywood legend Arnold Schwarzenegger’s environmental organisations.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.